Delivery Order SPE2DB24D2012-SPE2DB25FBVEP

Award Date 1/30/25
Potential Completion Date 1/31/25
Potential Value $12K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract is for the delivery of DAPAGLIFLOZIN 10 MG TABLET 30S, with a ceiling value of $5,772.53 and a period of performance through January 31, 2025. This is a delivery order contract with a firm fixed price pricing type. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of Dapagliflozin 5 mg tablets. The contract has a ceiling value of $1,631.11 and an ultimate completion date of September 19, 2024. It is a firm-fixed-price contract and does not have a set-aside designation. The award is associated with a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,506.68 firm fixed-price contract is for the delivery of dapagliflozin 10 mg tablets. The contract has an ultimate completion date of November 13, 2024 and was awarded on November 12, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,495.78, is for the delivery of DAPAGLIFLOZIN 10 MG TABLET 30S, a pharmaceutical product, with a completion date of February 4, 2025. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $1,159.64, is for the delivery of DAPAGLIFLOZIN 5 MG TABLET 30S, a medication used to treat type 2 diabetes. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Dapagliflozin 10 mg tablets, which are used to treat type 2 diabetes. The contract has a ceiling value of $13,655.93 and a completion date of July 12, 2024. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop...
This is a Delivery Order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4567054363 - Dapagliflozin 10 mg Tablets in 30-count packages, with a ceiling value of $1,195.93 and a completion date of January 28, 2025. The award is part of a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation for the supply of 4,565,825,260 units of dapagliflozin 5 mg tablets. The contract has a ceiling value of $1,588.40 and a completion date of September 17, 2024. The contract is a firm fixed-price delivery order, with no set-aside designation. AmerisourceBergen, a major pharmaceutical distributor, will supply these essential prescription medications to support various federal...
This federal contract award, valued at $2,518.66, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order to supply 4566964347 DAPAGLIFLOZIN 10 MG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of January 17, 2025 and is a firm fixed-price contract. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp., a major pharmaceutical distributor, for the supply of dapagliflozin 10 mg tablets. The contract is a firm fixed-price agreement with a ceiling value of $1,614.94 and a period of performance through July 2024. This delivery order is likely part of a larger Indefinite Delivery Contract (IDC) the company holds with DLA Troop Support Medical, valued up to $999,999,999, for providing a...
  • SPE2DB24D2012
    Indefinite Delivery Contract
  • SPE2DB24D2012-SPE2DB25FBVEP
    Delivery Order

This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract is for the delivery of DAPAGLIFLOZIN 5 MG TABLET 30S, a pharmaceutical product, with a ceiling value of $11,696.20 and a completion date of January 31, 2025.

The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 5/1/25, 9:56 AM